Skip to main content
Premium Trial:

Request an Annual Quote

Buying Bayer Rights, Celera Axes Axys Collaboration

NEW YORK, Oct. 8 - Celera Genomics has bought from Bayer all rights to preclinical research held under an existing collaboration between the two companies. In the process, Celera has untied a research partnership in place since before the Applera unit bought Axys Pharmaceuticals last year.


Celera has acquired rights to all compounds, study data, and relevant IP related to the use of the compounds in all fields, including the primary area of application, which in this case are potential asthma therapies.


Financial details were not disclosed.


"We plan to obtain pilot scale quantities of these compounds and to complete additional IND-enabling toxicology and safety evaluations in the coming months," Robert Booth, Celera's senior vice president of research and development, said in a statement this morning.


The companies agreed to terminate the collaborative research-and-license agreement penned in November 1994 by Arris Pharmaceutical, a predecessor of Axys Pharmaceuticals, a company Celera bought in November 2001. The company operates as Celera South San Francisco.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.